January 20, 2015
Pangaea Express: First Canadian biosimilar comes in at 30%+ discount over brand
The Canadian Drug Expert Committee (CDEC) final recommendation for Inflectra (the biosimilar of infliximab) was posted on the CADTH (Canadian Agency for Drugs and Technologies in Health) January 5th, 2015.
The CDEC recommended the listing for Health Canada approved indications (Rheumatoid Arthritis, ankylosing spondylitis, plaque psoriasis and psoriatic arthritis). With a submitted price of $650 per 100mg vial, treatment will be more than 34% less costly in comparison to the brand.
It is expected that Inflectra will be subject to a PCPA (pan-Canadian Pharmaceutical Alliance) negotiation prior to public reimbursement although nothing has been announced.